AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Clene to Submit ALS New Drug Application in Q4 2025
ByAinvest
Thursday, Aug 14, 2025 8:43 am ET1min read
Clene plans to analyze neurofilament light data from its NIH-sponsored Early Access Protocol in Q4 2025. The company will hold a Type C meeting with the FDA in Q3 2025 to discuss the survival benefit of CNM-Au8 dosing. A New Drug Application for potential accelerated approval of CNM-Au8 in ALS is expected in Q4 2025. A Type B end-of-Phase 2 meeting with the FDA will be held in Q3 2025 to discuss the MS clinical development program. Clene has $7.3 million in cash and cash equivalents as of June 30, 2025, with additional funding raising its cash runway into Q1 2026.
Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, reported its second quarter 2025 financial results and provided updates on its ALS and MS development programs. The company announced key meetings with the FDA and plans to submit a New Drug Application (NDA) for its ALS treatment program by the end of 2025. Financial highlights include a cash position of $7.3 million as of June 30, 2025, with additional funding extending its runway into Q1 2026.Clene reported a net loss of $7.4 million for the quarter, driven by reduced operating expenses. Research and development (R&D) expenses were $3.5 million, down from $4.2 million in Q2 2024, primarily due to cost-saving initiatives and decreased personnel expenses. General and administrative (G&A) expenses were $2.4 million, down from $3.3 million in Q2 2024, mainly due to cost-saving measures and decreased stock-based compensation expenses.
The company announced plans to analyze neurofilament light (NfL) biomarker data from its NIH-sponsored Early Access Protocol (EAP) in Q4 2025. A Type C meeting with the FDA is scheduled for Q3 2025 to discuss the survival benefit of CNM-Au8 dosing. Additionally, a Type B end-of-Phase 2 meeting with the FDA is planned for Q3 2025 to discuss the MS clinical development program. Clene expects to submit an NDA for potential accelerated approval of CNM-Au8 in ALS by the end of 2025.
Clene has $7.3 million in cash and cash equivalents as of June 30, 2025, with additional funding raising its cash runway into Q1 2026. The company's commitment to developing impactful therapeutic agents for neurodegenerative diseases remains unwavering.
[1] https://www.stocktitan.net/news/CLNN/clene-reports-second-quarter-2025-financial-results-and-recent-sho6g811e3i6.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet